Prosecution Insights
Last updated: August 15, 2026
Application No. 18/842,265

AZAPHILONE COMPOUND AND USE THEREOF IN PREPARATION OF ANTI-TUMOR DRUGS

Non-Final OA §102§112
Filed
Aug 28, 2024
Priority
Feb 28, 2022 — CN 202210186481.4 +1 more
Examiner
JACKSON, SHAWQUIA
Art Unit
Tech Center
Assignee
Ocean University Of China
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
3m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
1426 granted / 1830 resolved
+17.9% vs TC avg
Minimal -3% lift
Without
With
+-3.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
46 currently pending
Career history
1851
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
15.0%
-25.0% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
50.7%
+10.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1830 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-19 are currently pending in the instant application. Applicants have amended claims 1-10, 13, 15-18 and added new claim 19 in an amendment filed on May 1, 2025. Claims 2, 5-7, 9, 11-14 and 16-19 are rejected and claims 1, 3-4, 6, 10 and 15 are objected in this Office Action. I. Priority The instant application is a 371 of PCT/CN2022/137267, filed on December 7, 2022 and claims benefit of Foreign Application CHINA 202210186481.4, filed on filed on December 28, 2022. II. Information Disclosure Statement The information disclosure statement (IDS) submitted on November 27, 2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner. III. Rejections Claim Rejections - 35 USC § 112 The following is a quotation of the second paragraph of 35 U.S.C. 112: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2, 5, 6, 7, 12, 13 and 14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claims 2, 5, 6,7 and 12-14, the phrase "preferably" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Applicants are suggested to delete the part of the limitation that has “preferably” to overcome the rejection. Claims 7, 14 and 17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claims 7 and 17, the phrase "such as" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Applicants are suggested to delete the part of the limitation that has “such as” to overcome the rejection. Claim 7 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Specifically, the term “including” is considered open-ended language when not clearly defined and therefore is including additional subject matter into the method claims that is not described in the instant specification and is not particularly pointed out or distinctly claimed. This rejection can be overcome, for example, by amending the phrase “include but are not limited to” so that it now reads “are selected from” in claims 7 and 17. Claim 9 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The term “enhancing” in claim 9 is a relative term which renders the claim indefinite. The term “enhancing” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Applicants are suggested to cancel claim 9 to overcome the rejection. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless - (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 11-14 and 16-19 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Baker, et al. (US 2022/0016075 A1). The instant invention claims PNG media_image1.png 294 827 media_image1.png Greyscale PNG media_image2.png 368 824 media_image2.png Greyscale The Baker, et al. reference teaches azaphilone derivatives such as PNG media_image3.png 97 286 media_image3.png Greyscale (See page 1, compound III) wherein R1 is –(CH2)2OH; X is N; R3 is C6alkenyl substituted with C1 alkyl groups; R2 is Cl; R4 is -C(O)-CH3. These compounds are useful for treating infections caused by Mycobacterium tuberculosis. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above. IV. Objections Dependent Claim Objections Dependent Claim 15 is objected to as being dependent upon a rejected based claim. To overcome this objection, Applicant should rewrite said claims in an independent form and include the limitations of the base claim and any intervening claim. Claim Objections Claim 1-19 are objected to because of the following informalities: the claims contain the phrase “or its pharmaceutically acceptable salts, stereoisomers” which should read “or its pharmaceutically acceptable salts or stereoisomers”. Appropriate correction is required. V. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is 571-272-9043. The examiner can normally be reached on 7:00 AM-3:30PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /SHAWQUIA JACKSON/ Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Aug 28, 2024
Application Filed
Jul 15, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12692237
CONTINUOUS METHOD FOR PREPARING TRICYANOIMIDAZOLE
3y 1m to grant Granted Jul 28, 2026
Patent 12692242
METHOD FOR PREPARING FLURALANER
2y 4m to grant Granted Jul 28, 2026
Patent 12685311
NOVEL ENVIRONMENTALLY FRIENDLY BIOCIDAL QUATERNIZED AMINE COMPOUND
2y 10m to grant Granted Jul 21, 2026
Patent 12686668
LEUKOTRIENE SYNTHESIS INHIBITORS
2y 4m to grant Granted Jul 21, 2026
Patent 12668571
SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28
3y 4m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
75%
With Interview (-3.3%)
2y 3m (~3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1830 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month